Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter forms alliances against blood clotting disorders
If the collaboration is successful it could lead to treatments that reduce the frequency of injections required to treat blood clotting disorders such as hemophilia A. Lipoxen will
If the collaboration is successful it could lead to treatments that reduce the frequency of injections required to treat blood clotting disorders such as hemophilia A. Lipoxen will
In conjunction with a request from the FDA, Lilly submitted to regulatory agencies an analysis of adverse event data from its Strattera clinical trials database that identified a
The study achieved its goal of demonstrating the ability to deliver the drug, PTH1-34, and produce a similar pharmacokinetic profile to Forteo, an already approved subcutaneous treatment for
The collaboration will also aim to discover and develop other novel RNAi-based therapeutics against gene targets relating to eye diseases. Sirna will receive an initial payment of $5
Angeliq, already available in Europe, will be available in the US by prescription in a preparation containing 0.5mg drospirenone and 1mg estradiol. Angeliq is different from other available
This trial is being conducted under an investigational new drug application, filed with the Food and Drug Administration in April this year. The trial is a multi-center trial
Merck will receive an up-front payment of E60 million, as well as significant milestone payments. The companies say that they have a formula for splitting profits, with Merck
Dainippon will retain Japanese rights to the drug and co-promote the compound with Eisai in major countries. AS-3201 is designed to improve the symptoms of diabetic neuropathy, a
Zyflo was first approved to treat asthma in the US in 1996. Critical Therapeutics acquired worldwide rights to the drug and other formulations of zileuton in late 2003
The deal positions GE as a major player in the health care IT world–a market in which it sees great potential for growth as hospitals and health care